Credence

Evotec Wins $2.9M Gates Foundation Grant to Expand Stem Cell-Based Drug Safety Research


Key Points

  • Evotec received a $2.9 million Gates Foundation grant extending its stem cell-based drug safety collaboration for three years
  • The platform uses human induced pluripotent stem cells to identify developmental safety risks earlier in drug discovery
  • During the initial collaboration, Evotec screened more than 5,000 compounds across nine grantee programs

Evotec has received a $2.9 million grant from the Gates Foundation to continue developing and applying its human stem cell-based technology for evaluating potential developmental safety risks associated with experimental drug candidates.

The three-year award extends a collaboration that began in 2023, giving researchers involved in global health initiatives continued access to Evotec’s New Approach Methodologies (NAMs). The technology is designed to identify compounds that could interfere with fetal development, providing an opportunity to assess potential safety concerns earlier in the drug discovery process.

The platform uses human induced pluripotent stem cells (hiPSCs) to model aspects of human development and evaluate how potential drug candidates affect developing cells. By generating human-relevant safety data, the approach can help researchers make more informed decisions about which compounds warrant further investigation and clinical development.

During the initial three-year collaboration, Evotec screened more than 5,000 compounds across nine grantee programs. The results demonstrated the platform’s capacity to support large-scale screening and provide early insights into potential developmental toxicity.

“Identifying potential safety risks early in the drug development process is essential to the efficient advancement of better medicines for global health priorities,” says Dr. Joanna Holbrook, chief scientific officer at Evotec. She noted that the technology allows researchers to examine potential effects on prenatal development using human cell models, potentially reducing the need for costly changes later in development. Holbrook adds that the additional funding recognizes the value of the approach and will help make it available to a broader range of global health research programs.

The platform is part of Evotec’s expanding NAM capabilities, which are intended to improve the relevance of preclinical research while potentially reducing dependence on traditional animal testing. The company is also advancing other human-relevant models and computational tools to support drug efficacy and safety assessments.

Evotec’s NAM portfolio includes more than 25 hiPSC-derived cellular models, three-dimensional organoid systems, AI-supported disease modeling and high-throughput screening technologies. Together, these capabilities are designed to generate data that better reflects human biology and support decision-making throughout drug discovery and development.

Its human iPSC-based teratogenicity platform specifically addresses the early identification of potential developmental safety hazards. The in vitro screening system combines stem cell-derived models with automated workflows and high-content imaging to evaluate the effects of compounds on cellular processes associated with development.

The platform also draws on machine learning, genome-scale molecular data and high-throughput experimentation to support toxicity prediction across different organ systems. By identifying potential liabilities before candidates advance further into development, Evotec aims to help researchers prioritize compounds with more favorable safety profiles and improve the predictability of preclinical testing.

Learn more at www.evotec.com.